Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The p.E152K-STIM1 mutation deregulates Ca2+ signaling contributing to chronic pancreatitis.
Burgos M, Philippe R, Antigny F, Buscaglia P, Masson E, Mukherjee S, Dubar P, Le Maréchal C, Campeotto F, Lebonvallet N, Frieden M, Llopis J, Domingo B, Stathopulos PB, Ikura M, Brooks W, Guida W, Chen JM, Ferec C, Capiod T, Mignen O. Burgos M, et al. J Cell Sci. 2021 Feb 10;134(3):jcs244012. doi: 10.1242/jcs.244012. J Cell Sci. 2021. PMID: 33468626
STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia.
Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, Le Goux N, Vandier C, Potier-Cartereau M, Pers JO, Tempescul A, Berthou C, Bagacean C, Mignen O, Renaudineau Y. Debant M, et al. Among authors: burgos m. J Immunother Cancer. 2019 Apr 23;7(1):111. doi: 10.1186/s40425-019-0591-3. J Immunother Cancer. 2019. PMID: 31014395 Free PMC article.
Targeting basal-like breast tumors with bromodomain and extraterminal domain (BET) and polo-like kinase inhibitors.
Nieto-Jiménez C, Alcaraz-Sanabria A, Pérez-Peña J, Corrales-Sánchez V, Serrano-Heras G, Galán-Moya EM, Serrano-Oviedo L, Montero JC, Burgos M, Llopis J, Pandiella A, Ocaña A. Nieto-Jiménez C, et al. Among authors: burgos m. Oncotarget. 2017 Mar 21;8(12):19478-19490. doi: 10.18632/oncotarget.14465. Oncotarget. 2017. PMID: 28061448 Free PMC article.
Synthetic Lethality Interaction Between Aurora Kinases and CHEK1 Inhibitors in Ovarian Cancer.
Alcaraz-Sanabria A, Nieto-Jiménez C, Corrales-Sánchez V, Serrano-Oviedo L, Andrés-Pretel F, Montero JC, Burgos M, Llopis J, Galán-Moya EM, Pandiella A, Ocaña A. Alcaraz-Sanabria A, et al. Among authors: burgos m. Mol Cancer Ther. 2017 Nov;16(11):2552-2562. doi: 10.1158/1535-7163.MCT-17-0223. Epub 2017 Aug 28. Mol Cancer Ther. 2017. PMID: 28847989
CD5 expression promotes IL-10 production through activation of the MAPK/Erk pathway and upregulation of TRPC1 channels in B lymphocytes.
Garaud S, Taher TE, Debant M, Burgos M, Melayah S, Berthou C, Parikh K, Pers JO, Luque-Paz D, Chiocchia G, Peppelenbosch M, Isenberg DA, Youinou P, Mignen O, Renaudineau Y, Mageed RA. Garaud S, et al. Among authors: burgos m. Cell Mol Immunol. 2018 Feb;15(2):158-170. doi: 10.1038/cmi.2016.42. Epub 2016 Aug 8. Cell Mol Immunol. 2018. PMID: 27499044 Free PMC article.
Inhibition of the mitotic kinase PLK1 overcomes therapeutic resistance to BET inhibitors in triple negative breast cancer.
Nieto-Jimenez C, Galan-Moya EM, Corrales-Sanchez V, Noblejas-Lopez MDM, Burgos M, Domingo B, Montero JC, Gomez-Juarez M, Picazo-Martinez MG, Esparis-Ogando A, Pandiella A, Ocaña A. Nieto-Jimenez C, et al. Among authors: burgos m. Cancer Lett. 2020 Oct 28;491:50-59. doi: 10.1016/j.canlet.2020.06.020. Epub 2020 Jul 28. Cancer Lett. 2020. PMID: 32735909 Free article.
484 results